-
公开(公告)号:CA2506491A1
公开(公告)日:2005-11-19
申请号:CA2506491
申请日:2005-05-05
Applicant: SERVIER LAB
Inventor: DE NANTEUIL GUILLAUME , BENOIST ALAIN , COMBETTES MURIELLE , HARLEY ELIZABETH
IPC: C07D295/18 , A61K31/40 , A61K31/4025 , A61K31/426 , A61K31/427 , A61K31/438 , A61P3/10 , A61P43/00 , C07D207/06 , C07D207/10 , C07D207/16 , C07D277/06 , C07D277/12 , C07D295/185 , C07D311/96 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D417/12 , C07D277/04
Abstract: Composé de formule (I): (voir formule I) dans laquelle: .cndot. X1 représente un atome ou groupement choisi parmi CR4a R4b, O, S(O)q 1 et NR5, où R4a, R4b, q1 et R5 sont tels que définis dans la description, .cndot. m1 représente zéro ou un entier compris entre 1 et 4 inclus, .cndot. m2 représente un entier compris entre 1 et 4 inclus, .cndot. n1 et n2, identiques ou différents, représentent chacun un entier compris entre 1 et 3 inclus, .cndot. R1 représente un atome d'hydrogène ou un groupement choisi parmi carboxy, alkoxycarbonyle, carbamoyle éventuellement substitué et alkyle éventuellemen t substitué, .cndot. R2 représente un atome d'hydrogène ou un groupement alkyle, .cndot. Ak représente une chaîne alkylène éventuellement substituée, .cndot. p représente zéro, 1 ou 2, ~ .ident. R3 représente un atome d'hydrogène ou un groupement cyano, .cndot. X2 et X3, identiques ou différents, représentent chacun, soit un groupement S(O)q2, soit un groupement CR6a R6b, où q2, R6a et R6b sont tels que définis dans la description, ses isomères optiques lorsqu'ils existent, ainsi que ses sels d'addition à u n acide pharmaceutiquement acceptable. Médicaments.
-
公开(公告)号:RS50526B
公开(公告)日:2010-05-07
申请号:RSP20070392
申请日:2005-05-18
Applicant: SERVIER LAB
Inventor: DE NANTEUIL GUILLAUME , BENOIST ALAIN , COMBETTES MURIELLE , HARLEY ELIZABETH
IPC: C07D295/18 , C07D405/12 , A61K31/40 , A61K31/4025 , A61K31/426 , A61K31/427 , A61K31/438 , A61P3/10 , A61P43/00 , C07D207/06 , C07D207/10 , C07D207/16 , C07D277/06 , C07D277/12 , C07D295/185 , C07D311/96 , C07D401/12 , C07D403/12 , C07D409/12 , C07D417/12
-
公开(公告)号:MY139481A
公开(公告)日:2009-10-30
申请号:MYPI20052248
申请日:2005-05-18
Applicant: SERVIER LAB
Inventor: NANTEUIL GUILLAUME DE , BENOIST ALAIN , COMBETTES MURIELLE , HARLEY ELIZABETH
IPC: C07D295/18 , A61K31/40 , A61K31/4025 , A61K31/426 , A61K31/427 , A61K31/438 , A61P3/10 , A61P43/00 , C07D207/06 , C07D207/10 , C07D207/16 , C07D277/06 , C07D277/12 , C07D295/185 , C07D311/96 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D417/12
Abstract: COMPOUND OF FORMULA (&Igr;): WHEREIN: • X1 REPRESENTS AN ATOM OR GROUP SELECTED FROM CR4AR4B, O, S(O)Q1 AND NR5, WHEREIN R4A, R4B, Q1 AND R5 ARE AS DEFINED IN THE DESCRIPTION, • M1 REPRESENTS ZERO OR AN INTEGER OF FROM 1 TO 4 INCLUSIVE, • M2 REPRESENTS AN INTEGER OF FROM 1 TO 4 INCLUSIVE, • N1 AND N2, WHICH MAY BE IDENTICAL OR DIFFERENT, EACH REPRESENT AN INTEGER OF FROM 1 TO 3 INCLUSIVE, • R1 REPRESENTS A HYDROGEN ATOM OR A GROUP SELECTED FROM CARBOXY, ALKOXYCARBONYL, OPTIONALLY SUBSTITUTED CARBAMOYL AND OPTIONALLY SUBSTITUTED ALKYL, • R2 REPRESENTS A HYDROGEN ATOM OR AN ALKYL GROUP, • AK REPRESENTS AN OPTIONALLY SUBSTITUTED ALKYLENE CHAIN, • P REPRESENTS ZERO, 1 OR 2, • R3 REPRESENTS A HYDROGEN ATOM OR A CYANO GROUP, • X2 AND X3, WHICH MAY BE IDENTICAL OR DIFFERENT, EACH REPRESENT EITHER A S(O)Q2 OU OF A CR6AR6B GROUP, WHEREIN Q2, R6A AND R6B ARE AS DEFINED IN THE DESCRIPTION, ITS OPTICAL ISOMERS, WHERE THEY EXIST, AND ITS ADDITION SALTS WITH A PHARMACEUTICALLY ACCEPTABLE ACID. MEDICAMENTS.
-
公开(公告)号:ES2290864T3
公开(公告)日:2008-02-16
申请号:ES05291066
申请日:2005-05-18
Applicant: SERVIER LAB
Inventor: DE NANTEUIL GUILLAUME , BENOIST ALAIN , COMBETTES MURIELLE , HARLEY ELIZABETH
IPC: C07D295/18 , C07D405/12 , A61K31/40 , A61K31/4025 , A61K31/426 , A61K31/427 , A61K31/438 , A61P3/10 , A61P43/00 , C07D207/06 , C07D207/10 , C07D207/16 , C07D277/06 , C07D277/12 , C07D295/185 , C07D311/96 , C07D401/12 , C07D403/12 , C07D409/12 , C07D417/12
Abstract: Compuesto de fórmula (I): donde: * X1 representa un átomo o un grupo seleccionado de entre CR4aR4b, O, S(O)q1 y N-R5, representando R4a y R4b, idénticos o diferentes, cada uno, un átomo de hidrógeno o un grupo alquilo(C1-C6) lineal o ramificado, o bien R4a y R4b forman, junto con el átomo de carbono que los porta, un grupo cicloalquilo(C3-C7), q1 representa cero, 1 ó 2, y R5 representa un átomo de hidrógeno o un grupo alquilo(C1-C6) lineal o ramificado, eventualmente sustituido con un grupo hidroxilo, * m1 representa cero o un número entero comprendido entre 1 y 4, ambos inclusive, * m2 representa un númerto entero comprendido entre 1 y 4, ambos inclusive, * n1 y n2, idénticos o diferentes, representan cada uno un número entero comprendido entre 1 y 3, ambos inclusive, * R1 representa un átomo de hidrógeno o un grupo seleccionado de entre carboxilo, alcoxicarbonilo(C1-C6) lineal o ramificado, carbamoílo, eventualmente sustituido con 1 o 2 grupos alquilo(C1-C6) lineales o ramificados, y alquilo(C1-C6) lineal o ramificado eventualmente sustituido con un grupo hidroxilo o amino, eventualmente sustituido con 1 ó 2 grupos alquilo(C1-C6) lineales o ramificados, * R2 representa un átomo de hidrógeno o un grupo alquilo(C1-C6) lineal o ramificado, * Ak representa una cadena alquileno(C1-C4), lineal o ramificada, eventualmente sustituida con uno o varios átomos de halógeno, preferentemente de flúor, * p representa cero, 1 ó 2, * R3 representa un átomo de hidrógeno o un grupo ciano, * X2 y X3, idénticos o diferentes, representan cada uno, o bien un grupo S(O)q2, donde q2 representa cero, 1 ó 2, o bien un grupo CR6aR6b, donde R6a y R6b, idénticos o diferentes, representan cada uno un átomo de hidrógeno o de halógeno, preferentemente flúor, o bien R6a representa un átomo de hidrógeno y R6b representa un grupo hidroxilo, sus isómeros ópticos, cuando existan, así como sus sales de adición de un ácido farmacéuticamente aceptable.
-
公开(公告)号:EA009292B1
公开(公告)日:2007-12-28
申请号:EA200500683
申请日:2005-05-18
Applicant: SERVIER LAB
Inventor: DE NANTEUIL GUILLAUME , BENOIST ALAIN , COMBETTES MURIELLE , HARLEY ELIZABETH
IPC: C07D295/18 , C07D405/12 , A61K31/40 , A61K31/4025 , A61K31/426 , A61K31/427 , A61K31/438 , A61P3/10 , A61P43/00 , C07D207/04 , C07D207/06 , C07D207/10 , C07D207/16 , C07D277/06 , C07D277/12 , C07D295/185 , C07D311/96 , C07D401/12 , C07D403/12 , C07D409/12 , C07D417/12
Abstract: Предложеносоединениеформулы (I)вкоторой Xпредставляетсобойатомилигруппу, выбраннуюиз CRR, О, S(O)и NR, где Rи R, которыемогутбытьодинаковымиилиразными, каждыйпредставляетсобойатомводородаили C-С-алкильнуюгруппу, или Rи Rвместес атомомуглерода, ккоторомуониприсоединены, образуютС-С-циклоалкильнуюгруппу, qпредставляетсобой 0 или 2, и Rпредставляетсобойатомводородаили C-С-алкильнуюгруппу, замещеннуюгидроксигруппой, mпредставляетсобой 0 илицелоечислоот 1 до 4 включительно, mпредставляетсобойцелоечислоот 1 до 4 включительно, nи n, которыемогутбытьодинаковымиилиразными, каждыйпредставляетсобойцелоечислоот 1 до 3 включительно, Rпредставляетсобойатомводорода, карбамоилилиС-С-алкил, замещенныйгидроксигруппой, Rпредставляетсобойатомводорода, Ak представляетсобойС-С-алкиленовуюцепь, рпредставляетсобой 1, Rпредставляетсобойатомводородаилицианогруппу, ХиХ, которыемогутбытьодинаковымиилиразными, каждыйпредставляетсобойили S(O)группу, вкоторой qпредставляетсобой 0, или CRRгруппу, вкоторой Rи R, которыемогутбытьодинаковымиилиразными, каждыйпредставляетсобойатомводородаилиатомгалогена, или Rпредставляетсобойатомводорода, а Rпредставляетсобойгидроксигруппу, егоизомеры, еслионисуществуют, иегосолиприсоединенияс фармацевтическиприемлемойкислотой. Предложенспособполученияэтихсоединений, ихприменениеи фармацевтическаякомпозицияобладающаяактивностьюингибиторадипептидилпептидазы IV (DPP IV).
-
公开(公告)号:SI1598350T1
公开(公告)日:2007-10-31
申请号:SI200530030
申请日:2005-05-18
Applicant: SERVIER LAB
Inventor: DE NANTEUIL GUILLAUME , BENOIST ALAIN , COMBETTES MURIELLE , HARLEY ELIZABETH
IPC: C07D295/18 , C07D405/00 , A61K31/00 , A61K31/40 , A61K31/4025 , A61K31/426 , A61K31/427 , A61K31/438 , A61P3/00 , A61P3/10 , A61P43/00 , C07D207/06 , C07D207/10 , C07D207/16 , C07D277/06 , C07D277/12 , C07D295/185 , C07D311/96 , C07D401/00 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/00 , C07D409/12 , C07D417/00 , C07D417/12
-
公开(公告)号:AU2005202180A1
公开(公告)日:2005-12-08
申请号:AU2005202180
申请日:2005-05-19
Applicant: SERVIER LAB
Inventor: COMBETTES MURIELLE , NANTEUIL GUILLAUME DE , HARLEY ELIZABETH , BENOIST ALAIN
IPC: C07D295/18 , A61K31/40 , A61K31/4025 , A61K31/426 , A61K31/427 , A61K31/438 , A61P3/10 , A61P43/00 , C07D207/06 , C07D207/10 , C07D207/16 , C07D277/06 , C07D277/12 , C07D295/185 , C07D311/96 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D417/12 , C07D211/60 , C07D211/38 , A61K31/397 , A61K31/453 , C07D205/04 , C07D277/04
Abstract: Spiro-cycloalkyl N-acyl pyrrolidine or thiazolidine derivatives (I), their optical isomers and acid addition salts are new. Spiro-cycloalkyl N-acyl pyrrolidine or thiazolidine derivatives of formula (I), and their optical isomers and acid addition salts, are new. X 1CR 4aR 4b, O, S(O) q1 or NR 5; R 4a and R 4bhydrogen or 1-6 C linear or branched alkyl or together complete a 3-7C cycloalkyl; q1 : 0-2; R 5hydrogen or 1-6C linear or branched alkyl, optionally substituted by hydroxy; m1 : 0-4; m2 : 1-4; n1 and n2 : 1-3; R 1hydrogen, carboxy, 1-6C linear or branched alkoxycarbonyl, carbamoyl (optionally substituted by 1 or 2 1-6C linear or branched alkyl), or 1-6C linear or branched alkyl (optionally substituted by hydroxy) or amino (optionally substituted by 1 or 2 1-6C linear or branched alkyl); R 2hydrogen or 1-6C linear or branched alkyl; Ak : 1-4C linear or branched alkylene, optionally substituted by one or more halo, particularly fluoro; p : 0-2; R 3hydrogen or cyano; X 2 and X 3S(O) q2 or CR 6aR 6b; R 6a and R 6bhydrogen or halo, preferably fluoro, or R 6a = hydrogen and R 6b = hydroxy; and q2 : 0-2. An independent claim is also included for the preparation of (I). [Image] ACTIVITY : Antidiabetic; Anorectic. MECHANISM OF ACTION : Inhibition of dipeptidyl-peptidase IV (DPPIV). The compound (2S)-1-({[9-(hydroxymethyl)-3-oxaspiro[5,5]undec-9-yl]amino}acetyl)-2-pyrrolidinecarbonitrile had IC 50 76.1 nM against porcine renal DPPIV, in an assay based on cleavage of Gly-Pro-p-nitroanilide.
-
公开(公告)号:FR2870538A1
公开(公告)日:2005-11-25
申请号:FR0405454
申请日:2004-05-19
Applicant: SERVIER LAB
Inventor: DE NANTEUIL GUILLAUME , BENOIST ALAIN , COMBETTES MURIELLE , HARLEY ELIZABETH
IPC: C07D295/18 , A61K31/40 , A61K31/4025 , A61K31/426 , A61K31/427 , A61K31/438 , A61P3/10 , A61P43/00 , C07D207/06 , C07D207/10 , C07D207/16 , C07D277/06 , C07D277/12 , C07D295/185 , C07D311/96 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D417/12 , C07D277/04
Abstract: Composé de formule (I) :dans laquelle :- X1 représente un atome ou groupement choisi parmi CR4aR4b, O, S(O)q1 et NR5, où R4a, R4b, q1 et R5 sont tels que définis dans la description,- m1 représente zéro ou un entier compris entre 1 et 4 inclus,- m2 représente un entier compris entre 1 et 4 inclus,- n1 et n2, identiques ou différents, représentent chacun un entier compris entre 1 et 3 inclus,- R1 représente un atome d'hydrogène ou un groupement choisi parmi carboxy, alkoxycarbonyle, carbamoyle éventuellement substitué et alkyle éventuellement substitué,- R2 représente un atome d'hydrogène ou un groupement alkyle,- Ak représente une chaîne alkylène éventuellement substituée,- p représente zéro, 1 ou 2,- R3 représente un atome d'hydrogène ou un groupement cyano,- X2 et X3, identiques ou différents, représentent chacun, soit un groupement S(O)q2, soit un groupement CR6aR6b, où q2, R6a et R6b sont tels que définis dans la description,ses isomères optiques lorsqu'ils existent, ainsi que ses sels d'addition à un acide pharmaceutiquement acceptable.Médicaments.
-
公开(公告)号:NO20052414L
公开(公告)日:2005-11-21
申请号:NO20052414
申请日:2005-05-19
Applicant: SERVIER LAB
Inventor: NANTEUIL GUILLAUME DE , BENOIST ALAIN , COMBETTES MURIELLE , HARLEY ELIZABETH
IPC: C07D295/18 , A61K31/40 , A61K31/4025 , A61K31/426 , A61K31/427 , A61K31/438 , A61P3/10 , A61P43/00 , C07D207/06 , C07D207/10 , C07D207/16 , C07D277/06 , C07D277/12 , C07D295/185 , C07D311/96 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D417/12 , C07D207/14
Abstract: Spiro-cycloalkyl N-acyl pyrrolidine or thiazolidine derivatives (I), their optical isomers and acid addition salts are new. Spiro-cycloalkyl N-acyl pyrrolidine or thiazolidine derivatives of formula (I), and their optical isomers and acid addition salts, are new. X 1CR 4aR 4b, O, S(O) q1 or NR 5; R 4a and R 4bhydrogen or 1-6 C linear or branched alkyl or together complete a 3-7C cycloalkyl; q1 : 0-2; R 5hydrogen or 1-6C linear or branched alkyl, optionally substituted by hydroxy; m1 : 0-4; m2 : 1-4; n1 and n2 : 1-3; R 1hydrogen, carboxy, 1-6C linear or branched alkoxycarbonyl, carbamoyl (optionally substituted by 1 or 2 1-6C linear or branched alkyl), or 1-6C linear or branched alkyl (optionally substituted by hydroxy) or amino (optionally substituted by 1 or 2 1-6C linear or branched alkyl); R 2hydrogen or 1-6C linear or branched alkyl; Ak : 1-4C linear or branched alkylene, optionally substituted by one or more halo, particularly fluoro; p : 0-2; R 3hydrogen or cyano; X 2 and X 3S(O) q2 or CR 6aR 6b; R 6a and R 6bhydrogen or halo, preferably fluoro, or R 6a = hydrogen and R 6b = hydroxy; and q2 : 0-2. An independent claim is also included for the preparation of (I). [Image] ACTIVITY : Antidiabetic; Anorectic. MECHANISM OF ACTION : Inhibition of dipeptidyl-peptidase IV (DPPIV). The compound (2S)-1-({[9-(hydroxymethyl)-3-oxaspiro[5,5]undec-9-yl]amino}acetyl)-2-pyrrolidinecarbonitrile had IC 50 76.1 nM against porcine renal DPPIV, in an assay based on cleavage of Gly-Pro-p-nitroanilide.
-
公开(公告)号:NO20052414D0
公开(公告)日:2005-05-19
申请号:NO20052414
申请日:2005-05-19
Applicant: SERVIER LAB
Inventor: NANTEUIL GUILLAUME DE , BENOIST ALAIN , COMBETTES MURIELLE , HARLEY ELIZABETH
IPC: C07D295/18 , A61K31/40 , A61K31/4025 , A61K31/426 , A61K31/427 , A61K31/438 , A61P3/10 , A61P43/00 , C07D207/06 , C07D207/10 , C07D207/16 , C07D277/06 , C07D277/12 , C07D295/185 , C07D311/96 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D417/12 , C07D
Abstract: Spiro-cycloalkyl N-acyl pyrrolidine or thiazolidine derivatives (I), their optical isomers and acid addition salts are new. Spiro-cycloalkyl N-acyl pyrrolidine or thiazolidine derivatives of formula (I), and their optical isomers and acid addition salts, are new. X 1CR 4aR 4b, O, S(O) q1 or NR 5; R 4a and R 4bhydrogen or 1-6 C linear or branched alkyl or together complete a 3-7C cycloalkyl; q1 : 0-2; R 5hydrogen or 1-6C linear or branched alkyl, optionally substituted by hydroxy; m1 : 0-4; m2 : 1-4; n1 and n2 : 1-3; R 1hydrogen, carboxy, 1-6C linear or branched alkoxycarbonyl, carbamoyl (optionally substituted by 1 or 2 1-6C linear or branched alkyl), or 1-6C linear or branched alkyl (optionally substituted by hydroxy) or amino (optionally substituted by 1 or 2 1-6C linear or branched alkyl); R 2hydrogen or 1-6C linear or branched alkyl; Ak : 1-4C linear or branched alkylene, optionally substituted by one or more halo, particularly fluoro; p : 0-2; R 3hydrogen or cyano; X 2 and X 3S(O) q2 or CR 6aR 6b; R 6a and R 6bhydrogen or halo, preferably fluoro, or R 6a = hydrogen and R 6b = hydroxy; and q2 : 0-2. An independent claim is also included for the preparation of (I). [Image] ACTIVITY : Antidiabetic; Anorectic. MECHANISM OF ACTION : Inhibition of dipeptidyl-peptidase IV (DPPIV). The compound (2S)-1-({[9-(hydroxymethyl)-3-oxaspiro[5,5]undec-9-yl]amino}acetyl)-2-pyrrolidinecarbonitrile had IC 50 76.1 nM against porcine renal DPPIV, in an assay based on cleavage of Gly-Pro-p-nitroanilide.
-
-
-
-
-
-
-
-
-